Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies Corp. (DVAX)
NASDAQ:DVAX
DVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.74 - $13.89
Previous CloseN/A
Volume272.71K
Average Volume (3M)1.82M
Market Cap
$1.75B
Enterprise Value$1.22B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)102.3
Beta0.47
Next Earnings
May 01, 2025EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding131,454,560
10 Day Avg. Volume1,824,826
30 Day Avg. Volume1,822,665
Standard Deviation0.22
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.60
Price to Cash Flow (P/CF)22.10
P/FCF Ratio22.30
Enterprise Value/Market Cap0.69
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.67
Enterprise Value/Ebitda47.73
Forecast
1Y Price Target
$25.25Price Target Upside89.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Dynavax News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company expects positive net income for the full year 2024, indicating financial health and profitability.
Market OpportunityDynavax anticipates that the expanded market opportunity for vaccination against Hepatitis-B in the U.S. could grow to $900M by 2030, with Heplisav-B achieving at least 60% total market share.
Shareholder ValueDynavax announced a $200M share repurchase program of the company's common stock.
Bears Say
Product DiscontinuationThe Tdap program was discontinued due to an undifferentiated profile.
Sales DeclineDynavax expects that seasonality will reduce Q4 sales by approximately 15%.
Sales PerformanceHeplisav-B sales in 3Q24 did not meet the analyst's estimate and consensus, falling short of expectations.
---
Ownership Overview
0.40% Insiders
17.15% Mutual Funds
37.21% Other Institutional Investors
20.73% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DVAX FAQ
What was Dynavax Technologies Corp.’s price range in the past 12 months?
Dynavax Technologies Corp. lowest stock price was $9.74 and its highest was $13.89 in the past 12 months.
What is Dynavax Technologies Corp.’s market cap?
Dynavax Technologies Corp.’s market cap is $1.75B.
When is Dynavax Technologies Corp.’s upcoming earnings report date?
Dynavax Technologies Corp.’s upcoming earnings report date is May 01, 2025 which is in 68 days.
How were Dynavax Technologies Corp.’s earnings last quarter?
Dynavax Technologies Corp. released its earnings results on Feb 20, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.041 by $0.009.
Is Dynavax Technologies Corp. overvalued?
According to Wall Street analysts Dynavax Technologies Corp.’s price is currently Undervalued.
Does Dynavax Technologies Corp. pay dividends?
Dynavax Technologies Corp. does not currently pay dividends.
What is Dynavax Technologies Corp.’s EPS estimate?
Dynavax Technologies Corp.’s EPS estimate is 0.04.
How many shares outstanding does Dynavax Technologies Corp. have?
Dynavax Technologies Corp. has 131,454,560 shares outstanding.
What happened to Dynavax Technologies Corp.’s price movement after its last earnings report?
Dynavax Technologies Corp. reported an EPS of $0.05 in its last earnings report, beating expectations of $0.041. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Dynavax Technologies Corp.?
Currently, no hedge funds are holding shares in DVAX
---
Dynavax Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.25 (89.42% Upside)
$25.25 (89.42% Upside)
Blogger Sentiment
Neutral
DVAX Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 72.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.55%
12-Months-Change
Fundamentals
Return on Equity
3.18%
Trailing 12-Months
Asset Growth
9.15%
Trailing 12-Months
Company Description
Dynavax Technologies Corp.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
---
DVAX Company Deck
---
DVAX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a positive outlook for Dynavax, highlighted by record revenue growth, market leadership in hepatitis B vaccines, and promising clinical advancements. However, challenges remain in the approval of the hemodialysis vaccine and increasing R&D expenses.Read More>---
DVAX Stock 12 Month Forecast
Average Price Target
$25.25
▲(89.42% Upside)
Technical Analysis
Best Analysts Covering DVAX
1 Year
1 Year Success Rate
17/27 ratings generated profit
1 Year Average Return
+44.15%
reiterated a buy rating yesterday
Copying Matt Phipps's trades and holding each position for 1 Year would result in 62.96% of your transactions generating a profit, with an average return of +44.15% per trade.
---